Search results for: 'Interoperable digital health API'

23 Feb 2021  |  North America  |  Market Research

AI-Based Image Analysis Tools and Cloud-Based Deployment to Expand the Global Digital Pathology Market

Increased Demand for Remote Pathology Services and Centralization of Digital Pathology Workflow in Hospital Networks to Spark New Growth Opportunities

Infographics

×

The Transformational Health team at Frost & Sullivan provides critical insights into the global digital pathology market, highlighting key growth opportunities, market revenue forecast, and business models that will play an essential role in its growth. The study segments the market by product (hardware, software, and storage solutions) and region ...

04 Sep 2018  |  North America  |  Market Research

Digital Transformation in the Pharmaceuticals Industry—Companies-to-Action, 2018

Value-based Care, Patient Data Digitization, and Collaborative Technology Deployment Offer Investment Opportunities

Infographics

×

Key Issues Addressed

The pharmaceutical industry today is in a state of flux as it tries to maintain a delicate balance between the need for novel blockbuster drugs and the need for improved operational efficiencies in an increasingly competitive market space. As healthcare is becoming increasingly democratized, patients are emerging as key decision makers—digitally en...

16 Feb 2021  |  North America  |  Market Research

Smartphone-based Saliva Testing and Self-monitoring of Blood Glucose Driving the Digital POCT Market

Mobility Ecosystem Holds Bold Promise to Expand Patients’ Access to Care

Infographics

×

Smartphone-based devices and associated tools are becoming the ideal next-generation point-of-care testing (POCT) solutions for in vitro diagnostics. The global COVID-19 pandemic has led to frugal innovations in POCT. The World Health Organization (WHO) has endorsed POCT as the topmost research priority in response to the COVID-19 outbreak. Digital...

The growth trajectory of the global life sciences industry has benefited from a combination of novel technologies such as CRISPR-Cas9, microbiome and single-cell, relaxation of entry barriers in markets like China, and better-defined regulatory frameworks around next-generation therapies and companion diagnostics. A common denominator of growth a...

22 Oct 2018  |  North America  |  Market Research

Global Life Sciences Instrumentation and Research Tools Market, Forecast to 2023

Digitalization and M&As to Transform the Current Competitive Structure of the Industry

Infographics

×

Key Issues Addressed

The global life sciences instrumentation and research tools market is currently going through a transformation driven by ongoing market consolidation and technological innovation. Over the past five years, the industry has witnessed more than 50 mergers and acquisitions (M&A), which have resulted in a market consolidation at the top. Most of these ...

Healthcare is rapidly becoming patient-centric, focusing on outcomes and value. This offers clinical diagnostics players opportunities to advance their instrument, assay, and informatics capabilities to address unmet clinical needs and increase the precision diagnostics portfolio. Advances in next-generation sequencing-based companion diagnosti...

The Transformational Health team at Frost & Sullivan provides critical insights into the US clinical chemistry and immunoassay industry, highlighting the recent activities, key growth opportunities, and trends that are shaping the industry. The already dynamic in vitro diagnostics landscape in the United States was affected even more by the recen...

14 Mar 2022  |  North America  |  Market Outlook

Next-generation Diagnostics Outlook, 2022

Recovery in Routine Testing and Focus on Personalized Diagnostics to Propel Growth

Infographics

×

In vitro diagnostics introduces new technologies, sequencing methods, novel software algorithms, and multi-omics approaches to realise the goal of personalized medicine. Next-generation diagnostics has been the backbone of COVID-19-related emergency diagnosis, with an estimated 25% to 30% of revenue during 2020 and early 2021 related to this testin...

23 Aug 2022  |  North America  |  Frost Radar

Frost Radar™: US Liquid Biopsy, 2022

A Benchmarking System to Spark Companies to Action - Innovation that Fuels New Deal Flow and Growth Pipelines

Infographics

×

The oncology space is maturing rapidly. With the arrival of blood-based assays for cancer screening and the emphasis on early detection, the liquid biopsy segment is seeing increased consolidation and high-impact acquisitions, such as Illumina and GRAIL, Exact Sciences and Thrive Earlier Detection, and Roche Foundation Medicine and Lexent Bio. Comp...